How many investments has GV (Google Ventures) made?

GV (Google Ventures) has 299 tracked investments, 29 of which have exited via acquisition or IPO, including 33 dated in the last 24 months.

What stage does GV (Google Ventures) invest at?

GV (Google Ventures) invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is GV (Google Ventures)'s typical check size?

GV (Google Ventures) typically writes checks of $250K – $50M.

What sectors does GV (Google Ventures) focus on?

GV (Google Ventures) focuses on AI & Machine Learning, Biotech, Cloud Computing, Cybersecurity, Data & Infrastructure, Deep Tech, Developer Tools, Digital Health, Enterprise Software, Fintech, Hardware, Healthtech, Longevity, Medical Devices, Mental Health, Robotics, SaaS, Sector Agnostic, Semiconductors.

Where is GV (Google Ventures) located?

GV (Google Ventures) is headquartered in Mountain View, US.

Does GV (Google Ventures) lead rounds?

Yes, GV (Google Ventures) leads investment rounds.

Who does GV (Google Ventures) co-invest with?

GV (Google Ventures) most often shares deals with Andreessen Horowitz, ARCH Venture Partners, F-Prime Capital, among 687 tracked co-investors.

GV (Google Ventures)

Corporate VCoperating company · company profile

Mountain View · Seed–Late Stage · 54 people tracked

Also known as Google Ventures · GV

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into GV (Google Ventures)

3,376 people in our graph share verified history with the GV (Google Ventures) team — schools, employers, funds. One of them is your warm intro.

Niki Pezeshkiunlockedknows Crystal Huang · together at Goldman Sachs (overlapped)

×3knows the team · via Goldman Sachs

×3knows the team · via Harvard Business School

knows the team · via Brown University

knows the team · via Massachusetts Institute of Technology

knows the team · via Tufts Medical Center

✨ Fox Verdict

Investment thesis

GV has invested in AI and ML since its founding, starting with ML companies like Flatiron Health in 2012 and moving into core AI capabilities in 2016 with its backing of Lattice (later acquired by Apple). The firm has assembled a global portfolio of over 100 AI companies spanning the full AI stack, from infrastructure to life sciences to applications. GV believes the most valuable AI companies will reduce cost and complexity, prioritize real-world utility over sheer scale, and unlock exponential innovation across every domain.

Source: firm website, verified Aug 17, 2026.

Stage

Seed–Late Stage

Check

$250K – $50M

Mountain View, CA, US

Leads rounds

Leads

Instruments

Equity

Founded

2009

Last 12 months

60 investments

AUM

$13B

Tracked investments

551

Team · 54 people

from the firm's website & public directories

Anthony Philippakis· General Partner· Cambridge, Massachusettsin

A physician, genomicist, and data scientist, Philippakis is a general partner at GV investing at the intersection of life sciences and machine learning, with a focus on bringing genome sequencing and data science into clinical medicine. A former cardiologist at Brigham and Women's Hospital, he holds degrees from Yale, Cambridge, and Harvard, and spearheaded GV's incubation of Verve Therapeutics in 2016.

a•••@gv.comreveal

Ben Robbins· General Partner· Cambridge, Massachusettsin 𝕏

Ben Robbins is a psychiatrist-turned-investor with an MD/MBA and residency at Massachusetts General Hospital and McLean who leverages serious mental illness experience to evaluate clinical fit and provider workflow impact.

b•••@gv.comreveal

Brendan Bulik-Sullivan· General Partner· San Francisco, Californiain

General partner at GV focused on life sciences investments, interested in therapeutic biotechnology and diagnostics across all stages. Before GV, he worked on applied statistics and machine learning in genetics and biotech at Gritstone Oncology and the Broad Institute, with published research in Nature and Science. He holds a B.A. in mathematics from UC Berkeley and a Ph.D. in statistical genetics from Vrije Universiteit Amsterdam.

Crystal Huang· General Partner· New York, New Yorkin 𝕏

Crystal Huang is a general partner at GV focused on SaaS, infrastructure, and AI investments, with an emphasis on product- and developer-led adoption. She previously invested at NEA and Notable Capital (formerly GGV) and began her career in technology M&A at Blackstone.

David Krane· CEO & Managing Partner· San Francisco, Californiain 𝕏

David Krane leverages a communications and product PR background at Google to personally lead his firm's ~$258M Uber investment and frames deals through a Gen Z parent's dinner-table perspective.

d•••@gv.comreveal

David Schenkein· General Partner· Boston, Massachusettsin 𝕏

David Schenkein is a physician-investor, founding Agios CEO who oversaw metabolism‑targeting AML drug approvals, now a general partner who remains a clinician and warns non-dilutive deals can be more dilutive.

Erik Nordlander· General Partner· New York, New Yorkin 𝕏

Erik Nordlander combines MIT CS and graduate research in data extraction with Google engineering and tech‑lead experience, leads the New York office, and champions developer, cloud and AI infrastructure founders.

Frédérique Dame· General Partner· Bay Areain 𝕏

Frédérique Dame is a general partner at GV focused on disruptive consumer technologies, and helped start and leads GV's Women's Health investing team. She previously led product and engineering at Uber during its rapid scaling and worked at Yahoo!, Photobucket, and SmugMug.

Issi Rozen· General Partner· Cambridge, MAin

Issi Rozen is a general partner at GV focused on new company formation and early-stage life sciences investments. A former biotech executive and serial entrepreneur, he co-founded several startups including Verve Therapeutics and previously served as Chief Business Officer at the Broad Institute of MIT and Harvard. He holds an MBA from MIT Sloan and was formerly a jazz guitarist and Berklee College of Music professor.

i•••@gv.comreveal

Karim Faris· General Partner· San Francisco, Californiain 𝕏

Karim Faris leads investments in enterprise software, big data and security, using pattern recognition in modern data protection—led Cohesity's deal—and champions platforms that make secondary data accessible, analyzable and secure.

k•••@gv.comreveal

Michael McBride· General Partner· Bay Areain 𝕏

Michael McBride is a General Partner at GV based in San Francisco, leading early-stage enterprise technology investments including open-source and AI-driven companies. A Silicon Valley executive with a Mechanical Engineering background, he previously served as Chief Revenue Officer at GitLab, where revenue grew more than 100x, and held leadership roles at Meraki, Good Technology, Be, Inc., and Lookout.

Sangeen Zeb· General Partner· Bay Areain 𝕏

General Partner at GV focused on high-growth AI and enterprise investments across early and late-stage startups, with board seats at Harvey, OpenEvidence and Vercel. He joined GV in 2021 after roles at Founders Circle Capital, Centerview Capital, and Summit Partners.

s•••@gv.comreveal

Vidu Shanmugarajah· General Partner· Londonin 𝕏

Vidu Shanmugarajah is a Partner at GV (Google Ventures), where he invests in early-stage technology companies across AI, cloud infrastructure, biotech, enterprise, and consumer internet, typically at the Series A through Series B stages. Before entering venture capital, he began his career as a corporate lawyer at Linklaters, working on M&A, restructuring, and financing deals. He later moved into venture capital at Grafton Capital and into growth equity and business strategy at HgCapital. He also founded an online legal services platform called ConnexLaw. He is based in London and focuses on early-stage technology investing.

Dave Munichiello· Managing Partner· Bay Areain 𝕏

Dave Munichiello is a GV Managing Partner leading the firm's tech investing team across consumer, enterprise, and frontier areas, with a focus on data platforms, developer tools, infrastructure, and enterprise software. Before GV he was an early executive at Kiva Systems (later Amazon Robotics) and a combat veteran and former U.S. military Captain; he holds an MBA from Harvard Business School and a B.S. from Emory University.

Elena Sakach· Investment Partner· San Franciscoin 𝕏

Elena Sakach is an investment partner at GV based in San Francisco, focusing on fintech, software, and artificial intelligence. She previously was a partner at Coatue, where she led investments across fintech and software, and earlier worked in the TMT Investment Banking Division at Goldman Sachs and in TPG's Tech Investing Practice. Originally from the Midwest, she began her career in investment banking on Wall Street.

Karthik Ardhanareeswaran· Partner· Cambridge, Massachusettsin

An investing partner at GV focused on life sciences. Previously a VP and quant at D.E. Shaw developing algorithmic trading strategies, and earlier a stem cell and bioinformatics researcher at the Yale Child Study Center. Holds undergraduate and graduate degrees from Yale in Molecular, Cellular, and Developmental Biology.

KJ Sidberry· Partner· New York, New Yorkin 𝕏

KJ Sidberry is a New York-based investing partner at GV focused on early-stage consumer companies. Before GV he was an investor at Forerunner Ventures and previously worked as a consultant at Accenture and Boston Consulting Group; he holds a B.A. in computer science from Harvard.

Krishna Yeshwant· Managing Partner· Boston, Massachusettsin 𝕏

Krishna Yeshwant maintains an active clinical practice at Brigham and Women's Hospital, brings Google's early business development experience, spans biology to patient-facing software, and champions new long-horizon science funding models.

k•••@gv.comreveal

Luna Schmid· Partner· Londonin

London-based GV partner focused on technology investments across enterprise, consumer, AI and growth/early stages. She previously invested at Summit Partners' Venture Capital Fund, SoftBank's Vision Fund and Warburg Pincus, and began her career in investment banking at Morgan Stanley.

Sherry Chao· Partner· Bay Areain

Sherry Chao is an investing partner at GV, where she focuses on life sciences investments. She previously worked as a private equity investor at Goldman Sachs and as a cancer immunology researcher at the Broad Institute of MIT and Harvard. She holds a Ph.D. in computational biology and a BA in economics from Harvard, as well as an MBA from Harvard Business School.

Tom Hulme· Managing Partner· Londonin 𝕏

Tom Hulme is a founder-turned-VC, IDEO design director and OpenIDEO pioneer, who delivered 255x on Robinhood and applies a clock-speed lens to back AI and apps that compete with Alphabet.

t•••@gv.comreveal

Terri Burns· Partner

Andrew Wheeler· General Partner· San Francisco, Californiain

Andy Wheeler, a founder-operator and MIT Media Lab engineer with patents, built wireless mesh tech used in millions of smart meters and leads early agtech boards where automation meets farming.

Brian Bendett· Partner· San Francisco, Californiain 𝕏

Graham Spencer· General Partner· Palo Alto, Californiain 𝕏

Graham Spencer, a managing partner, combines first-cycle internet operating experience—co-founding/CTO of Excite.com—with a part-time CTO role at Synapticure and trusteeship at the Santa Fe Institute, merging building and complexity-science insight.

Jessica Verrilli· General Partner· San Francisco, Californiain 𝕏

Jessica Verrilli began her career at Twitter, which she joined in 2009 as an early employee and where she rose to VP of Corporate Development & Strategy, overseeing 30 acquisitions including Vine and Periscope over roughly 8.5 years. She co-founded the investment collective #ANGELS and has invested personally in more than 30 companies, and she most recently served as a General Partner at Google Ventures. She studied Human Biology at Stanford University, where she was a Mayfield Fellow.

j•••@adverb.vcreveal

Lo Toney· Partner· San Francisco, California, United Statesin 𝕏

Lo Toney, a former Zynga Poker GM, eBay leader, and LearnStreet CEO, incubated his firm inside GV, spun it out and backs seed VC managers—especially women and underrepresented founders—as meta-allocator.

M.G. Siegler· General Partner· San Francisco Bay Areain 𝕏

M.G. Siegler, a former TechCrunch columnist turned investor, applies a reporter's product-level scrutiny and shares unusually transparent, media-facing analysis via blogs and newsletters, bridging practitioner investing with public tech explanation.

Michael Margolis· Partner· Kirkland, Washingtonin 𝕏

Michael Margolis is a UX research consultant and author of Learn More Faster. He previously conducted over 300 research sprints at Google Ventures for early-stage companies across sectors including security, healthcare, biotech, medical devices, and ecommerce. He has contributed research methodology to design sprint practices and publishes writing on Medium.

Anika Gupta· Principal· Cambridge, Massachusettsin 𝕏

Anika Gupta is a principal at GV focused on biotech companies developing new therapeutics. She has prior experience in biotech formation and developed bioinformatics frameworks for patient stratification at Foundation Medicine and immunotherapy prediction at Merck. She holds a Ph.D. in bioinformatics and genomics from Harvard University and the Broad Institute, with doctoral research in single-cell genomics and autoimmune disease genetics, and a B.S. in Computer Science and Molecular Biology from MIT.

Anika Gupta Vatsa· Principal· Cambridge, MAin

Principal at GV focused on building and investing in biotech companies developing new medicines; she sits on the boards of EpiBiologics and Pretzel Therapeutics. Before GV she helped form several biotech startups and built bioinformatics frameworks at Foundation Medicine and Merck, and holds a Ph.D. in bioinformatics and genomics from Harvard/Broad Institute and a B.S. from MIT.

Roni Hiranand· Principal· Hong Kongin 𝕏

London-based investment principal at GV focused on early and late-stage companies in frontier and enterprise technology. Previously invested at Ant Financial's Bace Capital and Vectr Ventures on early-stage deals, and lectured on food science at the University of Hong Kong, where he earned a BA in History.

Han Hua· Principal· San Francisco Bay Areain 𝕏

Han Hua is a co-founder at a stealth-stage company focused on supercomputing. Previously, he was an investor at GV with a focus on AI, software, deep tech, and fintech, and earlier served as an engineer and product manager at Google working on payments, emerging markets, and blockchain technologies.

Cathy Friedman· Executive Venture Partner· United Statesin

Cathy Friedman is an Executive Venture Partner at GV with nearly 40 years of experience across banking, technology, and life sciences. She previously spent nearly 24 years at Morgan Stanley, where she was a managing director and co-head of the biotech practice, and later worked as an independent financial consultant and board member. At GV she is a senior member of the investing team and advises the firm's life sciences portfolio alongside Dan Lynch.

Dan Lynch· Executive Venture Partner· Boston, Massachusettsin 𝕏

Dan Lynch joined GV as an Executive Venture Partner and senior member of the life sciences team, in a newly created role focused on coaching CEOs and executives at emerging life sciences companies, identifying new investments, and mentoring the firm's life sciences team. He has spent decades in biotech as a CFO, CEO, and executive chairman, and has served as a board member or board chair of 16 companies since 2011. His work centers on advising biotech founders on talent, fundraising, and business development.

David Reshef· Venture Partner· San Francisco, Californiain

David Reshef is a computer scientist and physician serving as a venture partner at GV, focusing on machine learning, healthcare, and life sciences investments. He holds an M.D. from Harvard Medical School and a Ph.D. in computer science from MIT, and trained clinically in internal medicine and hematology/oncology.

•••reveal

Scott Biller· Executive Venture Partner· Boston, Massachusettsin

Dr. Scott Biller is an Executive Venture Partner at GV with a deep R&D background, having served as Chief Scientific Officer of Agios Pharmaceuticals and held leadership roles at Novartis and Bristol-Myers Squibb. He advises and sits on the boards of several biotech companies including Foghorn, Remix, Rome, and OMass Therapeutics.

Scott Davis· Venture Partner· San Francisco Bay Areain

Scott is a life sciences venture partner at GV and a professor of engineering at Dartmouth College focused on imaging strategies for understanding drug activity and guiding therapy. In a part-time role, he supports startups working on diagnostics and drug delivery platforms, drawing on his biomedical engineering background and prior startup experience.

Sridhar Ramaswamy· Entrepreneur in Residence & Venture Partner· Boston, Massachusettsin 𝕏

Joe Kraus· Venture Partner· Palo Alto, Californiain 𝕏

Joe Kraus is President of Lime, overseeing product, hardware design, engineering, supply chain, logistics, and software development. He co-founded Excite.com in 1993, which went public in 1996 and was sold in 2000, and JotSpot in 2004, which was acquired by Google in 2006. Before returning to operations at Lime, he served as a General Partner at Google Ventures for 10 years, investing in transportation and marketplace companies.

Mojca Skoberne· Entrepreneur in Residence· Greater Bostonin

Mojca Skoberne is an Entrepreneur in Residence at GV focused on building organizations and immune-system-based therapies. Prior to GV she held immunology and drug development leadership roles at Cogen/Repertoire Immune Medicines, Gritstone Oncology, and Genocea Biosciences, and holds a Ph.D. in Medical Sciences.

Mounisha Anumolu· Associate· New Yorkin

New York-based GV investor focused on AI across stages and the tech stack. Previously an investment banking analyst at Goldman Sachs in the TMT division working on enterprise software M&A, and interned at the Brookings Institution; holds a degree in Economics, Computer Science, and Public Policy from Dartmouth College.

Nicole Gaudelli· Entrepreneur in Residence· Los Altos, California, United Statesin

A life sciences entrepreneur in residence who joined GV in 2024, focused on the intersection of chemistry and biology and precision genetic medicines. She holds a chemistry Ph.D. from Johns Hopkins, invented the first adenine base editor during her Harvard/Broad Institute postdoc, and previously served as VP of gene editing at Beam Therapeutics.

Rishi Modi· Associate· San Franciscoin

Rishi Modi is an investor at GV focused on AI applications and infrastructure from seed to growth stages. Before joining GV in 2024, he was a tech IB analyst at J.P. Morgan and previously worked at Menlo Ventures, CyCognito, SVB Capital, Dell Tech Capital, and Citi Ventures; he studied Business and Data Science at UC Berkeley.

Sam Blackman· Entrepreneur in Residence· Seattle, Washington, United Statesin

Dr. Samuel Blackman is a physician-scientist, pediatric neuro-oncologist, and cancer drug developer who joined GV in 2025 as a life sciences entrepreneur in residence. He co-founded Day One Biopharmaceuticals in 2018 and previously held senior oncology drug development roles at companies including Merck, GlaxoSmithKline, Seattle Genetics, and Juno Therapeutics.

Braden Kowitz· San Francisco, Californiain 𝕏

Bradley Horowitz· Palo Alto, California, United Statesin 𝕏

Bradley Horowitz is a product executive at Google who invests and advises as an angel, with a portfolio of roughly 100 startups including Slack, Upstart, Grab, Miro, Coda and Sana. Alongside his investing, he is an entrepreneur, teaches at Cornell Tech, and serves as a board director for established companies, startups and non-profits. He earned a B.S. from the University of Michigan and an M.S. from MIT.

b•••@wisdomventuresfund.comreveal

Curtiss Pope· Winston-Salem, North Carolina, United Statesin 𝕏

Gaurav Chawla· San Francisco, Californiain

Mike Tsao· San Mateo, California, United Statesin

Oren Teich· Santa Rosa, California, United Statesin

Rosana Kapeller· Cambridge, Massachusettsin 𝕏

Ryan Tabone· Vice President· New York, New York, United Statesin

Sada Kurapati· Atherton, California, United Statesin 𝕏

Founder mafia

The GV (Google Ventures) mafia →

6 people who came through GV (Google Ventures) went on to found or lead other companies.

David SchenkeinGeneral PartnerFounded Agios Pharmaceuticals Issi RozenGeneral PartnerFounded Verve Therapeutics Sam BlackmanEntrepreneur in ResidenceFounded Day One Biopharmaceuticals Jessica VerrilliGeneral PartnerFounded Adverb Ventures Blake ByersGeneral PartnerFounded NewLimit Rosana KapellerFounded ROME Therapeutics

What they invest in

from 370 of 551 portfolio companies

AI & Machine Learning ×172Healthtech ×100Enterprise Software ×92SaaS ×82Biotech ×80Data & Infrastructure ×51Digital Health ×50Developer Tools ×44

HQs:United States×272United Kingdom×19Switzerland×3Netherlands×3Canada×2France×2

Who they back

founder profiles across 160 portfolio companies

39%

solo founders

63 of 160 mapped founding teams

48%

repeat founders

of 233 founders with career history

~4 yrs

old at investment

median across 78 dated deals

Founding team size:solo founder×632 founders×593 founders×174+ founders×21

Where their founders studiedfrom 208 founders with education data

Stanford University ×22Harvard University ×15University of California, Berkeley ×15Massachusetts Institute of Technology ×10Harvard Business School ×9Cornell ×7Carnegie Mellon University ×5Harvard Medical School ×5

What their founders studiedfrom 203 founders with field-of-study data

Computer Science ×81Engineering ×47Life Sciences ×32Business & Management ×23Economics ×19Medicine ×14Mathematics & Statistics ×10Humanities ×8

Where their founders worked beforefrom 233 founders with career history

Stanford University ×18Facebook ×8OpenAI ×8Goldman Sachs ×5Google ×5Massachusetts Institute of Technology ×5Morgan Stanley ×5Apple ×4

Accelerator rootsportfolio companies that came through a program

Y Combinator ×10 Entrepreneur First ×2 Plug and Play Ventures ×2 Techstars ×2

67 founders hold a PhD · 21 hold an MBA (of 218 with degree data) · backed the same founder in 2+ companies: 2 founders

Investments · 551 tracked

founders shown can be your intro path

By year:2026 · 44 2025 · 49 2024 · 44 2023 · 31 2022 · 41 2021 · 37 2020 · 17 2019 · 1 2018 · 10 2017 · 10 2016 · 6 2015 · 9303 dated

Prime Medicineprimemedicine.com in 𝕏NASDAQ: PRMESeries A · Oct 2019 · $120M✓ verified

Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.

BiotechDeep TechHealthtechMedical Devices

Andrew Anzalone(Co-founder and Head of Platform)in David Liu(Co-founder)inAllan Reine(Chief Executive Officer)in Mohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in

Co-investorsARCH Venture Partners Newpath Partners F-Prime Capital OUP (Osage University Partners)Samsara BioCapital

1Life Healthcare inNasdaq (historical; delisted after acquisition): ONEMAug 2018acquired by Amazon · Jul 2022 · $3.9B

1Life Healthcare operated One Medical, a membership-based primary care organization offering in-person clinics and virtual care across the United States.

Digital HealthHealthtechSan Francisco, US

Thomas H. Lee(Founder; former CEO)in Amir Dan Rubin(Former Chair and CEO)Paul S. Kirincich(Executive Officer)in Trent Green(Former CEO)in Andrew S. Diamond(Chief Medical Officer, Amazon One Medical; Head of One Medical Clinical Care Delivery)in Roy Schoenberg(Head of Amazon Health Services)in

Board seat Krishna Yeshwant· per SEC Form D

Co-investorsDag Ventures J.P. Morgan Asset Management Maverick Capital Oak Investment Partners Benchmark Pinnacle Ventures

Denali Therapeuticsdenalitherapeutics.com inNASDAQ: DNLIMar 2024SEC filingmedium confidence

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)in

Board seat David Schenkein· per SEC Form D · $499.7M raise · filed Mar 2024

Co-investorsARCH Venture Partners EcoR1 Capital F-Prime Capital Foresite Capital ARCH Venture Flagship Ventures

Adagio TherapeuticsNASDAQ: IVVDApr 2021 · $336M

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsFidelity Investments Foresite Capital MITHRIL Mithril Capital Management OrbiMed Polaris Partners +3 more

Barinthusbiobarinthusbio.com in 𝕏NASDAQ: BRNS

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical Devices

Geoffrey Lynn(Chief Scientific Officer)William Enright(Chief Executive Officer & Board Director)Leon Hooftman(Chief Medical Officer)

Co-investorsOxford Science Enterprises Milltrust International Group Xfund

Beam Therapeuticsbeamtx.com in 𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder and Inventor)inJ. Keith Joung(Founder and Inventor)inFeng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture Partners Dreamers VC Eight Roads Ventures F-Prime Capital Foresite Capital HongShan Capital Group +1 more

DocuSignNASDAQ: DOCU

DocuSign provides an Intelligent Agreement Management platform, e-signature solution, and contract lifecycle management software that organizations use to create, manage, and process business agreements; the company serves customers ranging from very small businesses to global enterprises across multiple industries and geographies.

Allan Thygesen(President, Chief Executive Officer)Blake Grayson(Executive Vice President, Chief Financial Officer)Robert Chatwani(President, General Manager, Growth)Paula Hansen(President, Chief Revenue Officer)James P. Shaughnessy(Chief Legal Officer)

EthosNASDAQ: LIFE

Ethos operates a digital platform that connects consumers, insurance agents, and carriers to facilitate the sale of life insurance and related products through direct consumer channels and a network of independent agencies.

Peter Colis(Chief Executive Officer and Chair of our Board of Directors)Lingke Wang(President and Director)Christopher Capozzi(Chief Financial Officer)Erin Lantz(Chief Revenue Officer)Vipul Sharma(Chief Technology Officer)

Co-investorsSequoia Capital Accel General Catalyst Heroic Ventures SoftBank Group

Freenomefreenome.com in 𝕏NASDAQ: FRNMOct 2015

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)inCharles Roberts(Director)inGabriel Otte(Director)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)

Co-investorsRA Capital Agent Capital AME Cloud Ventures Andreessen Horowitz Artis Ventures Asset Management Company +9 more

GitLabgitlab.com in 𝕏NASDAQ: GTLB

GitLab is an intelligent orchestration platform for DevSecOps that enables teams and AI agents to collaborate on the full software development lifecycle, from planning through deployment, with integrated security and compliance capabilities.

AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US

Sid Sijbrandij(Founder/CEO)inDmytro Zaporozhets(Founder/CTO)inDmitriy Zaporozhets(Cofounder)Paul Machle(Executive Officer)in

Board Bruce Armstrong(Director)in

Co-investorsAlkeon Innovation August Capital Base Partners Bling Capital Category Ventures Coatue Management +21 more

Invivydinvivyd.com in 𝕏NASDAQ: IVVD

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life Sciences Foresite Capital MRL Ventures Fund Premji Invest MITHRIL Mithril Capital Management +3 more

Lemonadelemonade.com in 𝕏NYSE: LMND

Lemonade is a digital insurance provider offering homeowners, renters, car, pet, and term life insurance policies.

AI & Machine LearningConsumerInsurTechNew York, US

Daniel Schreiber(Founder)in Shai Wininger(Founder)in Maya Prosor(Vice President, Distribution)in Adina Eckstein(Chief Operating Officer)in Tim Bixby(Chief Financial Officer)in John Peters(Chief Insurance Officer)in

Co-investorsAleph Allianz X Champel Capital Digital Horizon Digital Horizon VC EcoMachines Ventures +8 more

Maze Therapeuticsmazetx.com in 𝕏NASDAQ: MAZE

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Foresite Capital Frazier Life Sciences Janus Henderson Investors Third Rock Ventures +1 more

Monte Rosa Therapeuticsmonterosatx.com in 𝕏NASDAQ: GLUESeries B · Sep 2020 · $96M

Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.

AI & Machine LearningBiotechDeep TechHealthtechBoston, US

Markus Warmuth(M.D., Chief Executive Officer)in Sharon Townson(Ph.D., Chief Scientific Officer)in John Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)in Phil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in

Co-investorsAisling Capital New Enterprise Associates (NEA)Versant Ventures HBM Partners Amzak Health Avoro Capital Advisors +1 more

Nextdoor (NYSE: 2021)nextdoor.com in 𝕏NYSE: NXDR

Neighborhood social network; IPO 2021

AdTechSan Francisco, US

Nirav Tolia(Co-Founder, CEO, President & Chairperson of the Board)in Sarah Leary(Co-Founder, Chief of Marketing, Community & Business Operations)in Prakash Janakiraman(Co-Founder & Chief Architect)inDavid Wiesen(Co-Founder (Engineering))inIndrajit Ponnambalam(Chief Financial Officer)Sarah Friar(Former CEO, President & Chairperson)in

Co-investorsAxel Springer Digital Ventures Coatue Management Comcast Ventures Cota Capital Dag Ventures Dragoneer Investment Group +18 more

Parabilis Medicinesparabilismed.com inNASDAQ: PBLSSeries B · May 2018 · $66M

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)in

Co-investorsARCH Venture Partners Catalio Capital Management, LP Foresite Capital Frazier Life Sciences General Catalyst Nextech Invest +7 more

Taysha Gene Therapiestayshagtx.com in 𝕏NASDAQ: TSHA

Taysha Gene Therapies develops and commercializes gene therapies for monogenic diseases of the central nervous system, serving patients with rare and larger CNS conditions.

BiotechDeep TechDigital HealthHealthtechMedical DevicesTexas, US

R.A. Session II(Executive Officer, Director)in Sean P. Nolan(Chief Executive Officer and Board Chairman)in

Board Paul B. Manning(Director)in

Co-investorsBaird Goldman Sachs Jefferies PBM Capital

Tenaya Therapeuticstenayatherapeutics.com in 𝕏NASDAQ: TNYA

Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.

BiotechHealthtechSouth San Francisco, US

Deepak Srivastava, M.D.(Scientific Founder)inEric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)inSheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in

Co-investorsThe Column Group venBio Partners

Uberuber.com in 𝕏NYSE: UBER

Uber operates a multi-sided platform providing ride-sharing, food delivery, freight logistics, and business fleet management services across various global markets.

Logistics & Supply ChainMarketplacesMobility & TransportationSan Francisco, US

Travis Kalanick(Co-founder & CEO)Garrett Camp(Co-founder)Gautam Gupta(Executive Officer)inJeffrey Holden(Executive Officer)David Plouffe(Executive Officer)in Emil Michael(Executive Officer)in

Co-investors137 Ventures 408 Ventures A*ACME Capital Across Capital Partners Aglae Ventures +67 more

Tessltessl.io in 𝕏Seed · Nov 2024 · $125M✓ verified

Tessl builds an AI Native software development platform with tools for developers building with AI agents, centered on preserving intent and context rather than code.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaSLondon

Guy Podjarny(Founder & CEO)inKenneth MacAskill(Director)

BoardEdward Sim(Director)Carlos Gonzalez-Cadenas(Director)in

Board seat Tom Hulme· per SEC Form D

Co-investorsAccel Index Ventures boldstart ventures firstminute capital

Blockaidblockaid.io in 𝕏Feb 2025 · $50M✓ verified

Blockaid is a real-time onchain security platform for web3 builders, used to observe onchain assets, detect anomalies, and mitigate risk across blockchains, wallets, and connected web properties.

AI & Machine LearningCrypto & Web3CybersecuritySaaSNew York, US

Ido Ben-Natan(Co-Founder and CEO)inRaz Niv(Co-Founder and CTO)in Roni Sidi(General Counsel)in

Board Jason Risch(Board Observer / Director (Greylock investor representative))in

Co-investorsCyberstarts Greylock Partners Ribbit Capital Sequoia Capital Jibe Ventures Reverie +2 more

Cerevancecerevance.com in 𝕏Series B · May 2026 · $20M✓ verified

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

Craig Thompson(Chief Executive Officer)in Sagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)in Ottavio V. Vitolo(Chief Medical Officer)in

Co-investorsForesite Capital Dementia Discovery Fund SV Life Sciences Dementia Discovery Lightstone Ventures SV Health Investors +2 more

Clever Care Health Planclevercarehealthplan.com inSeries C · Mar 2023 · $42M✓ verified

Clever Care is a culturally and linguistically sensitive Medicare Advantage health plan serving Southern California that integrates Eastern and Western medicine approaches.

HealthtechInsurTechSouthern California, US

Myong Sun Lee(Executive Officer, Director)Hiep Dinh Pham(Executive Officer, Director)Dave Firdaus(Executive Officer, Director)

Co-investorsNorwest Venture Partners Global Founders Capital Novo Holdings AV8 Ventures Figure 8 Investments PruVen Capital Partners +1 more

Comanche Biopharmacomanchebiopharma.com inSeries A · Jan 2024 · $75M✓ verified

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.

BiotechFemTechHealthtechConcord, US

Mike Young(Founder)inT Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)

Board Brendan Bulik-Sullivan(Director)in

Co-investorsAtlas Venture Broadview Ventures F-Prime Capital Lilly Asia Ventures New Enterprise Associates (NEA)

Dopedope.security in 𝕏✓ verified

A cybersecurity company focused on improving user experience and product quality, positioning itself against vendors that prioritize marketing over practical solutions.

AI & Machine LearningCybersecurityEnterprise SoftwareSaaS

Kunal Agarwal(Founder & CEO)

Co-investorsPreface Ventures

DualEntrydualentry.com in 𝕏Series A · Oct 2025 · $90M✓ verified

DualEntry is an AI-native enterprise resource planning (ERP) platform designed to replace legacy accounting systems for mid-market to enterprise businesses.

AI & Machine LearningEnterprise SoftwareFintechSaaSNew York, US

Santiago Nestares(Co-founder)in Benedict Dohmen(Founder)in

Co-investorsContrary Khosla Ventures Lightspeed Venture Partners Carya Venture Partners Ludlow Ventures Outsiders +9 more

Fathomfathomhealth.com in 𝕏✓ verified

Fathom structures and organizes healthcare data to address inefficiencies in the healthcare system.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechOakland, US

Andrew(CEO)Chris(CTO)Enoch(COO)

Co-investorsLightspeed Venture Partners Founders Fund Alkeon Innovation Great Oaks Venture Capital Lifeforce Capital MBX Capital+2 more

Flapping Airplanesflappingairplanes.com 𝕏Jan 2026✓ verified

Flapping Airplanes is a foundational AI research lab working on the data efficiency problem, aiming to build models that reach human-level reasoning without training on vast amounts of data.

AI & Machine LearningDeep TechSan Francisco, US

ASHER SPECTOR(Executive Officer, Director)inBENJAMIN SPECTOR(Executive Officer, Director)Aidan Smith(Founder)in

Co-investorsIndex Ventures Argo Conviction Fundomo Menlo Ventures Sequoia Capital +1 more

Genie AIgenieai.co in 𝕏Series A · Oct 2024 · $17.8M✓ verified

Genie AI applies artificial intelligence to legal work, focusing on how businesses draft and transact legal contracts.

AI & Machine LearningEnterprise SoftwareLegalTechSaaSLondon, GB

Rafie Faruq(CEO)in Nitish Mutha(CTO)in

Co-investorsKhosla Ventures Entrepreneur First

Guildguild.ai in 𝕏✓ verified

Guild provides an observability and control runtime for AI agents, capturing full session traces of every model call, tool invocation, input, output, and decision at runtime.

AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise Software

James Everingham(Founder)in

Co-investorsAcrew Capital NFX Scribble Ventures Webb Investment Network

humans&humansand.ai 𝕏Feb 2024 · $480M✓ verified

humans& is a frontier AI lab focused on building human-centric AI systems that prioritize people and their relationships, emphasizing innovations in reinforcement learning, memory, and user understanding to create AI that strengthens organizations and communities.

AI & Machine LearningEnterprise SoftwareSaaSEl Segundo, US

Eric Zelikman(Co-founder)inNoah Goodman(Founder)inAlaarif Nooruldeen(Executive Officer, Director)

BoardKristen Green(Director)Allen Mask(Director)Jonathan Ellman(Director)

Co-investorsS32 SV Angel NVIDIA A.Capital Ventures Chamaeleon Felicis Ventures +7 more

Isomorphic Labsisomorphiclabs.com in 𝕏Series A · Mar 2025 · $600M✓ verified

Isomorphic Labs applies artificial intelligence to drug discovery, working to develop treatments for serious diseases.

AI & Machine LearningBiotechDigital HealthHealthtech

Demis Hassabis(Founder)in

Co-investorsCapitalG Alphabet MGX Temasek Thrive Capital Cathay Innovation +2 more

Leyden Labsleydenlabs.com in✓ verified

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.

BiotechDeep TechHealthtechLeiden, NL

Koenraad Wiedhaup(Founder & Chief Executive Officer)in Ronald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)in Dinko Valerio(Founder and Chair of the Supervisory Board)in Jintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in

Co-investorsClavystBio F-Prime Capital Bluebird Ventures Casdin Capital European Innovation Council Fund European Investment Bank +5 more

Mechanical Orchardmechanical-orchard.com in 𝕏Aug 2024 · $50M✓ verified

Mechanical Orchard develops software for modernizing legacy mainframe systems, using its Imogen platform to rewrite applications based on their runtime behavior rather than code alone and to automate code generation and verification.

AI & Machine LearningCloud ComputingDeveloper ToolsEnterprise SoftwareSan Francisco, US

Rob Mee(Founder & CEO)in

Co-investorsFin Capital Emergence Capital Emergence Capital Partners Spider Capital Webb Investment Network Bloomberg Beta +3 more

Mechanical Orchardmechanicalorchard.com in 𝕏✓ verified

Mechanical Orchard modernizes legacy enterprise systems, including mainframes, by using an AI-driven, component-by-component approach that rebuilds and tests each part in a secure cloud environment before deployment.

AI & Machine LearningCloud ComputingDeveloper ToolsEnterprise SoftwareSan Francisco, US

Edward Hieatt(COO)in

Co-investorsEmergence Capital Fin Capital Summit Peak Investments

Mestagmestagtherapeutics.com in 𝕏✓ verified

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Susan Hill(Chief Executive Officer)in

Co-investorsSV Health Investors Forbion Northpond Ventures

Mestag Therapeuticsmestagtx.com in 𝕏Mar 2026 · $40M✓ verified

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

Susan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsForbion Johnson & Johnson Innovation – JJDC Northpond Ventures SV Health Investors JJDC

Monzomonzo.com in 𝕏✓ verified

Monzo is a UK digital bank offering personal and joint current accounts managed through a mobile banking app, with features including balance checking, UK and international transfers, cheque deposits, and arranged overdrafts.

ConsumerFintechLondon, GB

Tom Blomfield(Co-Founder & former CEO)in Jonas Templestein(Co-Founder & CTO)in Jason Bates(Co-Founder)in Paul Rippon(Co-Founder)in Gary Dolman(Co-Founder & former CFO)inSusan Adams(Executive Officer)in

Co-investorsCapitalG Hedosophia Tencent Holdings Passion Capital Accel Alpha Wave Global +11 more

Neo4jneo4j.com in 𝕏Sep 2020✓ verified

Neo4j develops a graph database and graph data platform used to build applications that leverage connected data, with products including AuraDB, Graph Data Science, and vector search for GraphRAG and GenAI use cases.

AI & Machine LearningData & InfrastructureEnterprise SoftwareSan Mateo, US

Emil Eifrem(Co-Founder and CEO)inMichael Asher(Executive Officer)

Board Lars Nordwall(Executive Officer)inMichael Treskow(Director)Emanuel Lang(Director)Christian Jepsen(Director)in

Co-investorsInovia Capital Creandum Eurazeo Dawn Capital F-Prime Capital One Peak +3 more

nPlannplan.io in 𝕏Jan 2026✓ verified

nPlan builds AI trained on a dataset of over 750,000 historical construction project schedules to forecast schedule risk, generate and check schedules, and support project controls for capital projects.

AI & Machine LearningConstruction TechSaaSLondon, GB

Dev Amratia(CEO & Co-Founder)in Alan Mosca(CTO & Co-Founder)in Jade Bouhmouch(Head of Operations)in

Co-investorsEntrepreneur First Pentech Ventures Suffolk Technologies Alphabet Chevron Technology Ventures IDEO +1 more

Omassomass.com in 𝕏Series B · Apr 2022 · $95M✓ verified

OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs.

BiotechDeep TechDigital HealthHealthtechMedical DevicesOxford, GB

Professor Dame Carol Robinson(Founder and Chair of Scientific Advisory Board)Idlir Liko(Founder)inJonathan Hopper(Vice President, Platforms and Founder)inHsin Yung (Jason) Yen(Founder)in Ros Deegan in

Co-investorsOxford Science Enterprises Sanofi Ventures Northpond Ventures

Paradigm Healthparadigmhealth.ai in✓ verified

Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process.

BiotechDigital HealthHealthtech

Kent Thoelke(Founder & CEO)inJonathan Hirsch(Chief Strategy and Growth Officer)Jay Trepanier(Chief Financial Officer)inElijah Meerson(Chief Technology Officer)in Michelle Lee(Chief Operating Officer)in

Co-investorsARCH Venture Partners General Catalyst Lux Capital JobsOhio Ventures

Pelagepelagepharma.com in 𝕏✓ verified

Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.

BiotechHealthtechLongevity

William Lowry(PhD)in Christina Weng(Chief Medical Officer)in Nathan Wheeler(Chief Operating Officer)in

BoardDaniel Gil(PhD)

Co-investorsARCH Venture Partners HAWKTAIL Visionary Ventures YK Bioventures

Polar Signalspolarsignals.com in 𝕏Seed · Aug 2021 · $4M✓ verifiedAcquired

Polar Signals develops software performance and reliability tooling, including continuous profiling, to help developers build faster and more reliable applications.

AI & Machine LearningCloud ComputingData & InfrastructureDeveloper ToolsClaymont, US

Frederic Branczyk(Founder & CEO)inThorbald Hansen(Executive Officer)

Co-investorsLightspeed Venture Partners Haystack Spark Capital Lorimer Ventures Amplify Partners

Santa Anasantaana.bio in✓ verified

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.

AI & Machine LearningBiotechHealthtechAlameda, US

Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)in Ansuman Satpathy(Scientific Founder)in Newman Yeilding(Chief Medical Officer)in

Co-investorsVersant Ventures Access Biotechnology Andreessen Horowitz RTW Investments L.P.TPG

Silver Lakesilverlake.com✓ verified

Waymo develops the Waymo Driver, an autonomous vehicle system that provides ride-hailing services across multiple metropolitan areas.

AI & Machine LearningHardwareMobility & TransportationRoboticsSemiconductorsMountain View, US

Raghib Hussain(Chief Executive Officer)Tekedra MawakanaDmitri Dolgov

Co-investorsAlphabet Andreessen Horowitz Bessemer Venture Partners CapitalG Dragoneer Investment Group DST Global +9 more

SpyBiotechspybiotech.com in 𝕏✓ verified

A biotech company dedicated to developing new vaccines, combining scientific expertise with commercial and operational capabilities.

BiotechDeep TechHealthtechMedical DevicesCambridge, GB

Mark Howarth(Co-founder)inSumi Biswas(President, Co-founder, Chief Scientific Officer)inSimon Draper(Co-founder)inJing Jin(Co-founder)in

Co-investorsOxford Science Enterprises

status prostatus.pro✓ verified

StatusPRO creates immersive virtual reality sports gaming experiences, primarily for the NFL, that let players and gamers practice athletic skills and compete in authentic game scenarios.

GamingHardwareMedia & EntertainmentSports Tech

Andrew Hawkins(Co-founder)Troy Jones(Co-founder & CEO)

Co-investorsAlumni Ventures Limited Ventures Digerati Investments Disney Accelerator JDS Sports TitletownTech

Synapse Healthsynapsehealth.com in✓ verified

Synapse Health manages the operational, administrative, and financial complexity of durable medical equipment (DME) for patients, prescribers, DME providers, and health plans.

Digital HealthHealthtechMedical DevicesEvanston, US

Anthony Kilgore(Executive Officer, Director)

BoardTodd Stern(Member of the Board of Directors of Issuer)Benjamin Robbins(Member of the Board of Directors of Issuer)Eitan Schechter(Member of the Board of Directors of Issuer)Cory Roberts(Cofounder and CEO)inAndrew Hayek(Member of the Board of Directors of Issuer)

Synthesiasynthesia.io in 𝕏Series B · Oct 2025 · $50M✓ verified

Synthesia is an AI video platform that lets businesses generate videos with AI avatars and agents, aimed at helping organizations train, onboard, and upskill employees.

AI & Machine LearningEnterprise SoftwareMarketing TechSaaSLondon, GB

Victor Riparbelli(Co-founder & CEO)in Steffen Tjerrild(Co-Founder & COO/CFO)in Lourdes Agapito(Co-Founder)in Matthias Niessner(Co-Founder)in

Co-investorsAccel Air Street Capital FirstMark Capital Kleiner Perkins MMC Ventures New Enterprise Associates (NEA)+13 more

Ultromicsultromics.com in 𝕏✓ verified

Ultromics develops AI models that analyze routine echocardiography studies to help clinicians detect HFpEF and screen for cardiac amyloidosis, delivered through a single workflow platform.

AI & Machine LearningDigital HealthMedical Devices

Ross Upton(Founder & CEO)in

Co-investorsOxford Science Enterprises Legal & General Future Planet Capital Nina Capital NovaCapital Optum Ventures +2 more

Anomalianomali.com in 𝕏Jan 2018

Anomali is a cybersecurity platform that combines a unified security data lake, threat intelligence, and agentic AI to help security teams detect, investigate, and respond to cyber threats.

AI & Machine LearningCybersecurityEnterprise SoftwareRedwood City, US

Hugh Njemanze(Executive Officer, Director)in

Board Steve Harrick(Director)inSteve Herrod(Director)Tom Reilly(Director)in

Board seat Karim Faris· per SEC Form D

Co-investorsGeneral Catalyst IVP (Institutional Venture Partners)Lumia Capital Paladin Capital Group Sozo Ventures Sprint Vc +2 more

Blacksmith Software inMay 2026

San Francisco, US

Aditya Jayaprakash(Executive Officer, Director, Promoter)Aayush Shah(Executive Officer, Director, Promoter)in Aditya Maru(Executive Officer, Director, Promoter)in

Board seat Erik Nordlander· per SEC Form D

CoreOScoreos.com in 𝕏Apr 2016acquired by Red Hat · Jan 2018

CoreOS developed container-focused infrastructure software, including the lightweight Container Linux operating system, the etcd distributed key-value store, and the Tectonic Kubernetes platform.

Cloud ComputingData & InfrastructureDeveloper ToolsEnterprise SoftwareSan Francisco, US

Alex Polvi(Founder/CEO)in Brandon Philips(Director)in

BoardMichael Abbott(Director)

Board seat Dave Munichiello· per SEC Form D

Co-investorsIntel Capital Kleiner Perkins Work-Bench Y Combinator Andreessen Horowitz Sequoia Capital

Crash Overridecrashoverride.com in 𝕏Seed · Feb 2025 · $28M

Crash Override monitors code written by humans and AI agents, inspects each build layer, applies cryptographic tagging to artifacts, and tracks their provenance in production environments.

CybersecurityDeveloper ToolsEnterprise SoftwareNew York, US

Mark Curphey(Director)in John Viega(Executive Officer, Director)in

BoardJay Allan Leek II(Director)Michael Droesch(Director)in Gerhard Eschelbeck(Director)in

Board seat Erik Nordlander· per SEC Form D

Co-investorsBessemer Venture Partners Firestreak Ventures Syn Ventures Seed Management Llc Essence Venture Capital SYN Ventures

Dandelion Energydandelionenergy.com in 𝕏Series A · Nov 2022 · $16M

Dandelion Energy designs and installs geothermal heating and cooling systems for homes, positioning geothermal as a primary heating and cooling solution for both new and existing residential buildings.

CleantechClimate TechEnergyHardwarePalo Alto, US

Kathy Hannun(Founder & CTO)inRajeev James Quazi(Executive Officer, Director)Dan Yates(CEO)in

Board Craig Shapiro(Director)in

Board seat Erik Nordlander· per SEC Form D

Co-investorsBreakthrough Energy Ventures Collaborative Fund Comcast Ventures Cool Climate Collective Energy Transition Ventures Ground Up Ventures +4 more

Dnanexusdnanexus.com in 𝕏Apr 2015

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.

AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US

Andreas Sundquist(Executive Officer, Director)in Richard Daly(Executive Officer, Director)inGeorge Asimenos, PhD(Chief Product Officer)in

BoardMichael Goldberg(Director)Geoff Duyk(Director)

Board seat Krishna Yeshwant· per SEC Form D

Co-investorsClaremont Creek Ventures Foresite Capital K9 Ventures Uncork Capital Wireframe Ventures

Element Sciencemyjewel.com inAug 2016SEC filingmedium confidence

Jewel is a wearable patch cardioverter defibrillator designed to provide continuous protection from sudden cardiac arrest, using machine learning to minimize false alarms while requiring no daily maintenance for up to a week.

AI & Machine LearningHealthtechMedical DevicesSan Francisco, US

Uday N. Kumar(Executive Officer, Director)in

BoardRussell Hirsch(Director)Neil Exter(Director)inWilliam H. Kucheman(Director)

Board seat Krishna Yeshwant· per SEC Form D · $25M raise · filed Aug 2016

Co-investorsThird Rock Ventures Deerfield Management Company

Fogpharmafogpharma.com inDec 2022SEC filingmedium confidence

FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases.

BiotechBoston, US

Gregory L Verdine(Executive Officer, Director)Mathai Mammen(CEO, President and Chairman)in

Board seat Krishna Yeshwant· per SEC Form D · $178M raise · filed Dec 2022

Co-investorsCatalio Capital Management, LP Horizons Ventures venBio Global Strategic

FullStoryfullstory.com in 𝕏Aug 2022

Fullstory captures real user behavior across digital products to power behavioral analytics and AI-driven insights.

AI & Machine LearningData & InfrastructureSaaSAtlanta, US

Scott Voigt(Executive Officer, Director)inH. Bruce Johnson, Jr.(Executive Officer, Director)Joel Webber(Founder)in

Board Ted Schlein(Director)

Board seat Karim Faris· per SEC Form D

Co-investorsGlynn Capital Management Kleiner Perkins Stripes Dell Technologies Capital Permira Salesforce Ventures +1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Altana Technologies, Inc.Decibel Therapeutics, Inc.dope.security inc.JenZ Mist Systems, Inc.Push Security, Inc.TwylaAdapterAgainAirtimeAppurifyArmadinAspireBeacon BiosignalsBitterroot BioBounti LabsBrightlineCardurion PharmaceuticalsCareBridgeCarmeraCheckmateChroma MedicineClearStory DataClever CareClimate-XCliQr TechnologiesCmdCognosysComplyanceComstructContinuaCosmos Entity, Inc.CourierDasient

Browse all 551 investments with full details →

▶351 more tracked companies

DataFoxDaydreamdbt Labs Deepset Delphia Therapeutics Delve Bio Denver Technologies Devoted Health Dialpad DigitsDistanceDiverge Health DriverDriverDuo Security Dyno Therapeutics EgnyteEgnyteElement Science Emergent VR Emissary Encoded Therapeutics Encodia EnduroSat Envelop VR Envise Epi Biologics EQRx Evelo EveloEveryONE MedicinesEvox Therapeutics Experience ExperienceFabricFarmers Business Network Farmwise Labs Fauna firsthandfirsthandFlapping AirplanesFlatiron Health Flick FlickFlickFlock FreightFlourishFlutterFlowFLX Bio Found Foundation Medicine Fyto Fyto Gate Bio Genesis Global Genie Genie Genie Genome Geometric Glass Imaging Graft Granata BioGravityGravity Gravity Sketch Gritstone Oncology Guide Therapeutics Guidelight Health Gusto Gyft Hanoverpark Harness HarveyHeadwayHebbiaHipsterHome From CollegeHomeAwayHomebound HomeLight Hyperfine Research IconOVir Bio Imagen Imagen Technologies Impossible Foods Included Health InertiaInertiaInfinitus Insitro Instawork Invetx Ionic Security Iora Health Iterative Iterative Health JauntJetJetifyJoyTunes Kabam Karma Karma Karma Kick KindbodyKinetic AppsKitchen UnitedKronos Bio LaBarge Weinstein Lakestar Lambda School Landis Lapse Lattice Laurel LawhiveLedgerXLightLightspeed Venture Partners Lime Loom Lore LoveveryLuminateLuxe Lytical Ventures Machinify Macroscope Magenta Therapeutics Managed by Q MatterMedallionMeltano Merida BiosciencesMetaviewMetsera Midi Midi Health MillMimicMimic NetworksMindMeldMirrorTab Mirvie Miso Modern Age Modular MokNMokNMoonhubMoonHubMoonwalk BiosciencesMother GamesMother.tech Motive Motive Technologies MSTMultiversemyLaurelmyLaurelMySQL NanitNava BenefitsNavier AInChroma BioNebexNebexNectar Nectar Nectar Nectar SocialNerd ApplyNest Neuralink Nimbus Nimbus Nimbus NimbusNothingNothing Tech Nova Labs NYMNym HealthOasis HealthOblenio Bio ObsidianOdysseyOmniOmni Omni OmniOmni AnalyticsOne Medical OpenEvidence Optimizely Orange Chef Orbital InsightOsmo LabsOula Health Overture LifePangeaPanorama Paradigm HealthPartifulPartnersPatinaPatina HealthPayRangePecan AI Peerspace Pei Pelage PharmaceuticalsPerceive BioPerceive BiotherapeuticsPerceive PharmaPercolata PeriscopePhoebePindropPixie LabsPlaid PostHog Pretzel TherapeuticsPrudentia SciencesPuppetQQuadraticRampReaction Read It Later Ready Responders Recursive Super Intelligence Redpanda RelayRides Resilience Resistant AIResistant AIRewire RhyGaze AG Rilla Ripcord RIPPL Care Roboflow Rocket Fuel Rocket Lawyer Rocketrip Rodin Therapeutics ROME TherapeuticsRoxRumr Santa Ana Bio Sardine Scale AI ScalyrScanScandit Scope3 Scout RFP Secret Escapes Segment Seismic TherapeuticSenseSense SensorumSideQuestSierra SiftSiftSift Signos Simply SingleStore SingleStore Skyport Systems SlackSnorkelSnorkel AI Snyk Solve HealthcareSolveAISolveAI Soylent Speakeasy SpeakeasySpeakeasySprinter Health Stackblitz StackOne Stipple Bio StockX Storj LabsStripestrongDM Student Experience Subtext SynackSynapticureSync LabsSyremis TherapeuticsSyremis TherapeuticsTamr Taylor Tend Tend Tennr The Players TribuneThinking MachinesThinking Machines Lab ThousandEyes Thumbnail for Gritstone Bio TMRW Life SciencesTrace NeuroscienceTranslucent AI Transphorm Treeline Biosciences Typeface UJET UniverseUrban EnginesUrban MachineUrsa ComputingVareto Ventus Ventus TherapeuticsVeobotVercel Versant Ventures VerseVerse EnterprisesVicinitas TherapeuticsViz Ai VocodeVocodeVoicea VoltageWaltz HealthWarpWatch ClubWatchClub TVWaymoWeaveworks Witness aiWonderYellowbrick DataYuga LabsZephyr Health Zipline Zipline Zipline

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 28

IPOs and acquisitions across the tracked portfolio

Prime MedicineNASDAQ: PRME1Life HealthcareNasdaq (historical; delisted after acquisition): ONEMDenali TherapeuticsNASDAQ: DNLIAdagio TherapeuticsNASDAQ: IVVDBarinthusbioNASDAQ: BRNSBeam TherapeuticsNASDAQ: BEAMDocuSignNASDAQ: DOCUEthosNASDAQ: LIFEFreenomeNASDAQ: FRNMGitLabNASDAQ: GTLBInvivydNASDAQ: IVVDLemonadeNYSE: LMNDMaze TherapeuticsNASDAQ: MAZEMonte Rosa TherapeuticsNASDAQ: GLUENextdoor (NYSE: 2021)NYSE: NXDRParabilis MedicinesNASDAQ: PBLSTaysha Gene TherapiesNASDAQ: TSHATenaya TherapeuticsNASDAQ: TNYAUberNYSE: UBERCoreOSacq. by Red HatMist Systems, Inc.acq. by Juniper NetworksAhanaacq. by IBMAppurifyacq. by GoogleAspireacq. by AnthemAspire Healthacq. by CareMore Health (Anthem)Astridacq. by YahooCacheflowacq. by HubSpotCelsius Therapeuticsacq. by AbbVie

Portfolio news

latest coverage across their companies

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use | BioPharma Dive

Nimbus · biopharmadive.com · Sep 11, 2026

Harvey hits $15.5B valuation, months after reaching $11B

Harvey · techcrunch.com · Sep 9, 2026

Amazon Leo Orders 6 More Ariane 64 Launches from Arianespace - Via Satellite

EnduroSat · satellitetoday.com · Sep 9, 2026

Uber invests $10M in Indian fleet operator Carrum at $168M valuation

Uber · techcrunch.com · Sep 9, 2026

Fundraising News | Page 6 | Financial IT

Cambium Capital · financialit.net · Sep 8, 2026

Prime Medicine to Participate in Upcoming September 2026 Investor Conferences - BioSpace

Prime Medicine · biospace.com · Sep 3, 2026

Cohesity - Wikipedia

Cohesity · en.wikipedia.org · Sep 2, 2026

Santa Ana, Costa Mesa Orange and San Clemente move to raise taxes and fees: What voters need to know - New Santa Ana

Santa Ana · newsantaana.com · Sep 2, 2026

IPO stake values · per SEC filings · 7

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Prime Medicine	13.0%	$17.00	Oct 2022	$212.2M
Parabilis Medicines	4.1%	$20.00	Jun 2026	$96.7M
Invivyd	5.2%	$17.00	Aug 2021	$96.6M
Adagio Therapeutics	5.2%	$17.00	Aug 2021	$96.6M
Ethos	12.4%	$19.00	Jan 2026	$71.6M
Maze Therapeutics	5.5%	$16.00	Jan 2025	$38.6M
Barinthusbio	5.0%	$17.00	Apr 2021	$29M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has GV (Google Ventures) made?: GV (Google Ventures) has 299 tracked investments, 29 of which have exited via acquisition or IPO, including 33 dated in the last 24 months.
What stage does GV (Google Ventures) invest at?: GV (Google Ventures) invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is GV (Google Ventures)'s typical check size?: GV (Google Ventures) typically writes checks of $250K – $50M.
What sectors does GV (Google Ventures) focus on?: GV (Google Ventures) focuses on AI & Machine Learning, Biotech, Cloud Computing, Cybersecurity, Data & Infrastructure, Deep Tech, Developer Tools, Digital Health, Enterprise Software, Fintech, Hardware, Healthtech, Longevity, Medical Devices, Mental Health, Robotics, SaaS, Sector Agnostic, Semiconductors.
Where is GV (Google Ventures) located?: GV (Google Ventures) is headquartered in Mountain View, US.
Does GV (Google Ventures) lead rounds?: Yes, GV (Google Ventures) leads investment rounds.
Who does GV (Google Ventures) co-invest with?: GV (Google Ventures) most often shares deals with Andreessen Horowitz, ARCH Venture Partners, F-Prime Capital, among 687 tracked co-investors.

Images

Co-investors · 550

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

$500K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

$500K – $15M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

$50K – $250M

Sequoia Capital

Sequoia Capital is a venture capital firm that partners with founders to build technology companies.

$4.4M – $214M

Accel

Accel is a venture capital firm that partners with exceptional teams, positioning itself as a first partner to founders globally.

$1.6M – $70M

Lightspeed Venture Partners

Lightspeed is a global venture capital firm that has spent over two decades backing innovative companies as an early and first investor.

Both backed · 23

$1.7M – $87M

SV Angel

SV Angel is a firm that has backed startup founders since the 1990s, leveraging a large network of founders, industry leaders, and regulators to support portfolio companies.

General Catalyst

General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.

Both backed · 20

Lemonade Parabilis MedicinesEthosAltana Anomali Beacon Biosignals Bowery Devoted Health Gusto Kick Lore Mirvie Modular Monzo Paradigm Health RIPPL Care Scale AI Sprinter Health Universe Vercel

$30M

Coatue Management

Coatue Management is a technology-focused investment firm that invests in innovation across both public and private markets with responsible risk management.

$1M – $20M

IVP (Institutional Venture Partners)

IVP (Institutional Venture Partners) is a venture capital firm that backs breakout companies at critical inflection points, helping them grow into enduring market leaders.

Both backed · 20

Nextdoor (NYSE: 2021)Uber Aledade Anomali Checkr Cribl Harness Laurel Lime Motive Technologies Obsidian Pindrop Slack Solve Healthcare Tennr The Players Tribune Twyla Vercel Yellowbrick DataHomeAway

$15M – $75M

Tiger Global Management

Tiger Global Management operates public equity strategies (long/short, long-focused and crossover) and a private equity business investing in early- through late-stage growth companies across new and existing industries.

$1M – $100M

▶538 more co-investors

F-Prime Capital New Enterprise Associates (NEA)Felicis Ventures Greylock Partners Index Ventures Menlo Ventures SoftBank Vision Fund Lux Capital Redpoint Ventures Bessemer Venture Partners Spark Capital Insight Partners Benchmark RA Capital Foresite Capital DCVC (Data Collective)Intel Capital Casdin Capital Foundation Capital Polaris Partners Qualcomm Ventures Techstars Notable Capital Canaan Partners Slow Ventures Venrock In-Q-Tel Craft Ventures Alumni Ventures Founder Collective First Round Capital True Ventures CRV (Charles River Ventures)Madrona Venture Group Thrive Capital Collaborative Fund S32 Third Rock Ventures BoxGroup Sound Ventures Norwest Venture Partners Atlas Venture Wing CapitalG Bain Capital Life Sciences Founders Fund Great Oaks Venture Capital Battery Ventures Oak HC/FT Kapor Capital Obvious Ventures Addition Shasta Ventures Dreamers VC Ballistic Ventures Comcast Ventures Greenoaks Northpond Ventures Versant Ventures Deerfield Management Company Bain Capital Ventures Union Square Ventures (USV)Balderton Capital Eniac Ventures FirstMark Capital Greycroft Scale Venture Partners Floodgate Acrew Capital OrbiMed Third Point Ventures Locus Ventures HOF Capital NGP Capital Foothill Ventures City Light Nextech Invest Workday Ventures Oxford Science Enterprises ACME Capital RRE Ventures Bling Capital Amplify Partners Lowercase Capital Threshold Ventures Matrix Coinbase Ventures General Atlantic NextGen Venture Partners boldstart ventures Tenaya Capital August Capital Spider Capital Work-Bench Preston-Werner Ventures M12 (Microsoft's Venture Fund)CrunchFund Flare Capital Partners Prelude Ventures Strawberry Creek Ventures Vista Venture Partners The Column Group Access Biotechnology SteelSky Ventures Long Journey Ventures Uncork Capital DST Global Sapphire Ventures Gradient Ventures Streamlined Ventures Susa Ventures AME Cloud Ventures Innovation Endeavors SignalFire Cota Capital Meritech Capital Partners Sherpalo Ventures Upfront Ventures Village Global Dell Technologies Capital Fuel Capital Standard Capital Next Play Ventures Scribble Ventures Webb Investment Network NewView Capital GreatPoint Ventures Ludlow Ventures Kyber Knight Capital Valor Equity Partners Dragoneer Investment Group Schematic Ventures venBio Partners Mithril Capital Management Eight Roads Ventures Digitalis Ventures Maverick Capital Shine Capital DFJ Mercury Fund Kaiser Permanente Ventures Bright Pixel Capital Uber Atomico Plug and Play Ventures Mayfield Fund NextView Ventures HCVC Fifth Wall Caffeinated Capital Emergence Capital Partners Bond Capital Management Resolute Ventures Ulu Ventures Sierra Ventures Crosslink Capital Revolution Next47 Ribbit Capital Maveron Point Nine 01 Advisors DCM Ventures Goodwater Capital Harrison Metal Tq Ventures Llc Kindred Ventures EQT Ventures Global Founders Capital TSVC General Partnership Chemistry Costanoa Ventures The Chernin Group (TCG Crypto)Eclipse Ventures Operator Collective Outlander VC March Capital Partners Lakestar High Alpha Decibel Partners Serena Ventures Lead Edge Capital Breakthrough Energy Ventures Peak XV Partners Mango Capital Allison Pickens Ventures Amadeus Capital Partners Walden International Altimeter Capital Yes VC Basis Set Ventures Xfund Artis Ventures Ten Eleven Evolution Equity Partners TRANSFORMATION CAPITAL Episode1 S Capital AllegisCyber Capital Walden Catalyst Accenture Ventures Sanofi Ventures Xplorer Capital Ascension Ventures Fin Capital Wellington Management Advance Venture Partners Novartis Venture Fund Aisling Capital Ingeborg Investments Define Ventures Optum Ventures Dolby Family Ventures DTCP Cleo Capital Expa Vida Ventures OpenAI Startup Fund Third Point Wireframe Ventures US Innovative Technology B Capital Group Quiet Capital Offline Ventures Liquid Ventures SciFi VC Freestyle Capital Forerunner Ventures PICUS CAPITAL Bowery Capital South Park Commons Bonfire Ventures Bullpen Capital Trinity Ventures Ridge Ventures Paradigm Base10 Partners 2048 Ventures WEEKEND Creandum Nexus Venture Partners Kortschak Investments L.P.Bitkraft Esports Ventures Two Sigma Ventures Accomplice Initialized Capital Cyberstarts AngelPad Speedinvest Entrée Capital Haun Ventures Notion Capital Moxxie Ventures MaC Venture Capital 468 Capital Passion Capital Bedrock Transmedia Capital CoinFund Freigeist Capital Javelin Venture Partners Nyca Partners Tusk Venture Partners Rocketship.vc Summit Partners Formation Group Contrary LocalGlobe K9 Ventures MMC Ventures Playground Global firstminute capital Future Perfect Ventures Zeev Ventures UP Partners Helium-3 Ventures Multicoin Capital Adverb Ventures Voyager Capital SAV (Scale Asia Ventures)Thomvest Ventures G2 Venture Partners Paladin Capital Group Bow Capital Dimension Capital Stripe Credo Ventures Anti Arrive MVP Ventures Atlantic Bridge Ventures BioGeneration Ventures f7 Ventures Kindred Capital MPM BioImpact Cambridge Innovation Capital Congruent Ventures Flagship Pioneering 7wire Ventures Arboretum Ventures Capnamic Roosh Ventures Sofinnova Ventures Vivo Capital Supernode Ventures Hatteras Venture Partners Safar Partners Element Partners DBL Partners Forefront Venture Illuminate Financial Lumia Capital Qiming Venture Partners S2G Investments 33N Pale Blue Dot SemperVirens Venture Capital VMG Partners Acre Venture Partners noa Thompson Hutton, LLC HealthCap iSelect Fund HBM Partners Carya Venture Partners Anterra Capital Bluebird Ventures RTW Investments L.P.Permira Buckhill Capital FJ Labs Unknown Ventures Everywhere Ventures Kraken SOSV Goat Capital Partech Ventures UpHonest Capital Pioneer C2 Investments Accel-KKR Lookout Ventures Flybridge Capital Partners Stride VC Practical Venture Capital Electric Capital Todd and Rahul’s Angel Fund Trajectory Ventures Buckley Ventures Management Company Llc Operator LP Hanabi Capital M13 Pantera Capital Uncorrelated Ventures Pareto Holdings Salesforce Japan Co.,Ltd.WGI Group Tribe Capital Firstlook Betaworks Ventures Management, Llc Causal Footwork HV Capital 7percent Ventures 23andMe Kearny Jackson Brainchild Holdings Draper Fisher Jurvetson (DFJ)Pelion Venture Partners Zetta Venture Partners Robot Ventures Cherry Ventures OurCrowd Vine Ventures 2xN Polychain Capital Upside Partnership American Express Ventures (Amex)Anorak Ventures Anthemis Venture Mucker Capital Polygon Coelius Capital Science Ventures Kohlberg Kravis Roberts foobar.vc Founders' Co-op Giant Ventures Global Llp Mosaic Ventures Recursive Ventures Expansive Ventures Jackson Square Ventures Crosscut Ventures Dig Ventures Management Limited Hoxton Ventures IVC Z47 Marcy Venture Partners Jetstream Third Kind Venture Capital Golden Ventures What If Ventures Presence Capital BDC Venture Capital Gutter Capital Notation Capital Smash Capital Vertex Ventures Israel Ravelin Capital Highbury Holdings Morado Venture Partners Kaszek Ventures Origin Ventures Presight Capital Venture Highway Convective Capital Sweet Capital cLabs Thirty Five Ventures (35V)Vertex Ventures Sea Management Pte. Ltd.Athletico Ventures Parade Ventures Possible Ventures Astanor Ventures IrishAngels Stealth Capital Trucks VC Angular Ventures AZ-VC Incisive Ventures Merus Capital Verified Capital 14W Glilot Capital Partners Race Capital Cyfrin Primetime Partners Defy Partners GE Ventures HC9 Ventures Jigsaw VC muru-D Primitive Ventures Incite.org Cherubic Ventures E1 Ventures Miramar Venture Partners Geek Ventures Moonfire Ventures OpenView Venture Partners Sofinnova Partners SR One Capital Management Toyota Ventures 8090 Industries Crane Venture Partners Portage Ventures Strata Capital Partners Syngenta Group Ventures Band of Angels Basecamp Fund Finch Capital Slack Fund Cambrian Ventures Okta Ventures Timespan Ventures Cambrian Asset Management GSR Ventures LiveOak Ventures Abingworth Equal Ventures Avalanche VC Jerusalem Venture Partners (JVP)Piva Capital Triatomic Capital Invariantes Fund Stanford University Cavalry Ventures MizMaa Ventures Sandbox Industries Morgenthaler Olima Ventures Thomson Reuters Ventures Bryant Stibel Amara VC Glencrest Group Telescope Partners Two Small Fish Ventures Framework Ventures Merak Ventures V3 Ventures Blisce Pitchdrive Airbus Ventures Fundamental Ventures Conductive Ventures MKT1 Capital Momenta Ventures Talis Capital Apollo Health Ventures Creative Destruction Lab (CDL)DVx Ventures The Venture Reality Fund Consensys Ventures Data Tech Interlock Partners +ND Capital Fitz Gate Ventures Grit Ventures Vensana Capital Rethink Education Berkeley Angel Network Untapped Capital Distributed Ventures Wasabi Ventures Berkeley Blockchain Xcelerator ARK Investment Management AfterWork Ventures L'ATTITUDE Ventures LearnStart Sure Ventures Aqua Spark Azolla Ventures Cyber Mentor Fund Ayuh Ventures Blueberry Ventures Banyan Ventures Bloom8 Microtraction PandaDoc Qiming Venture Partners USA Satori Capital Alma Angels Fusion VC Vree Ventures HighlandX Spacecadet Ventures Harvard Business School Alumni Angels of Greater New York Brand Capital

Firms observed investing alongside GV (Google Ventures), from public investor directories. Shared companies are the overlap with GV (Google Ventures)'s recorded portfolio.

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M

Everywhere Ventures

Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.

$250K

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

$100K – $10M

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Seed Investors & VC Firms in North America Investors & VC Firms in Europe Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States Investors & VC Firms in Global